Pluristem Announces South Korean Partner Files IND With Korean FDA
July 08, 2013 at 05:58 AM EDT
On the heels of announcing its strategic partnership agreement with Cha Bio&Diostech (Kosdaq:CHA) on June 26th, Pluristem Therapeutics Inc. (NASDAQ: PSTI ) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that Cha Bio&Diostech "Cha" has filed its first investigational new drug (IND) application for Pluristem's PLacental eXpanded
